Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021
June 22 2021 - 6:30AM
Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, today announced that it will release first quarter
2021 results on Thursday, July 1, 2021, and host a conference call
at 8:30 a.m. EDT to discuss financial results and recent corporate
developments.
The conference call will be available via phone and webcast. To
access the first quarter results call, please dial +1 (409)
220-9054 for U.S. callers, or +44 (0) 8000 323836 for international
callers, and reference passcode 4485380 approximately 15 minutes
prior to the call. To access the live audio webcast of the
conference call please visit the “Investors” section of company’s
website at https://www.affimed.com/investors/webcasts_cp/. A replay
of the call will be archived on the Affimed website for 30 days
after the call.
About Affimed N.V.Affimed (Nasdaq: AFMD) is a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer by actualizing the
untapped potential of the innate immune system. The company’s
proprietary ROCK® platform enables a tumor-targeted approach to
recognize and kill a range of hematologic and solid tumors,
enabling a broad pipeline of wholly-owned and partnered single
agent and combination therapy programs. The ROCK® platform
predictably generates customized innate cell engager (ICE®)
molecules, which use patients’ immune cells to destroy tumor cells.
This innovative approach enabled Affimed to become the first
company with a clinical-stage ICE®. Headquartered in Heidelberg,
Germany, with offices in New York, NY, Affimed is led by an
experienced team of biotechnology and pharmaceutical leaders united
by a bold vision to stop cancer from ever derailing patients’
lives. For more about the company’s people, pipeline and partners,
please visit: www.affimed.com.
Investor Relations ContactAlexander
FudukidisDirector, Head of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024